| October 29 |
 |
Conference Call for FY2012 2nd Quarter Business Results [Material][Audio]
⇒[Q&A](November 5, 2012) |
| October 29 |
 |
Announcement of FY2012 2nd Quarter Financial Results 
⇒R&D Pipeline "State of New Product Development" |
| October 26 |
|
Launch of TETRABIK Adsorbed Diphtheria-purified Pertussis-tetanus inactivated polio (Sabin strain) Combined Vaccine |
| October 19 |
|
Notice Regarding Dissolution of Capital Alliance with Choseido Pharmaceutical Co., Ltd. |
| October 11 |
|
CSR Report 2012 |
| October 10 |
|
Outcome of Global Phase III (EPPIC) Studies |
| October 1 |
|
Outsourcing of Logistics Operations |
| September 28 |
|
Application for time-window extension of the thrombolytic agents GRTPA and ACTIVACIN up to 4.5 hours after the onset of symptoms of ischemic cerebrovascular disease |
| September 20 |
|
Launch of "Simponi”, a human TNFα monoclonal antibody in Indonesia |
| September 13 |
|
MAINTATE Tablets: Selective β1 Antagonist
Notice regarding application for additional indication for chronic atrial fibrillation |
| August 31 |
|
Companies Submit Joint Application Seeking Approval for Additional Indication for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors, Amoxicillin Hydrate and either Clarithromycin or Metronidazole |
| August 31 |
|
Notice regarding dissolution of Bipha Corporation-related joint venture with Nipro Corporation |
| August 28 |
|
Launch of TENELIA 20mg Tablets
A DPP-4 Inhibitor for Type 2 Diabetes Mellitus Originating from Japan |
| July 31 |
|
Conference Call for FY2012 1st Quarter Business Results [Material][Audio]
⇒[Q&A](July 31, 2012) |
| July 31 |
|
Announcement of FY2012 1st Quarter Financial Results
⇒R&D Pipeline "State of New Product Development" |
| July 23 |
|
Launch of Tranquilizer, DEPAS TABLETS 0.25 mg |
| July 6 |
|
Launch of Argatroban, a Selective Antithrombin Agent, in UK |
| June 29 |
|
Marketing and Manufacturing Approval Received for TENELIA 20mg Tablets
A DPP-4 Inhibitor for Type 2 Diabetes Mellitus Originating from Japan |
| June 22 |
|
Notice of Resolution of the 5th Ordinary General Meeting of Shareholders
⇒Results of the Exercise of Voting Rights(June 25, 2012) |
| June 22 |
|
IR "Financial Data" |
| June 6 |
|
Launch of Pitavastatin Calcium, a Hypercholesterolemia Treatment Agent, in Taiwan |
| June 1 |
|
Termination of License Agreement with Cytochroma for MT-2832 (Generic Name: Lunacalcipol) as a Treatment for Secondary Hyperparathyroidism |
| May 15 |
|
Notice Regarding Transfer of Fine Chemical Operations |
| May 10 |
|
IR Meeting for FY2011 Business Results[Material] [Audio]
⇒[Q&A](May 18, 2012) |
| May 9 |
|
Launch of Pitavastatin Calcium, a Hypercholesterolemia Treatment Agent, in Indonesia |
| May 8 |
|
Announcement of Financial Results for FY2011
⇒R&D Pipeline "State of New Product Development" |
| May 8 |
|
Notice of Dividend of Retained Earnings |
| May 8 |
|
New Organization in Plasma Fractionation Operations
Establishment of “Japan Blood Products Organization” |
| May 8 |
|
Remicade for I.V. Infusion 100, Anti-Human TNF α Monoclonal Antibody
A New Option to Shorten Infusion Time |
| May 8 |
|
Remicade for I.V. Infusion 100, Anti-Human TNF α Monoclonal Antibody
Lifting of Condition on Approval for Psoriasis |
| May 7 |
|
VIVUS gains NDA approval for TA-1790 in the US |
| March 29 |
|
Launch of "SIMPONI”, a human TNFα monoclonal antibody in Taiwan |
| March 21 |
|
“IMUSERA Capsules 0.5mg” Multiple Sclerosis Treatment AgentNotice regarding revision of “warnings” and “important basic precautions” sections of prescribing information |
| March 7 |
|
Conclusion of Research Collaboration Agreement for Next-Generation Vaccines |
| March 6 |
|
Daiichi Sankyo and Mitsubishi Tanabe Pharma Establish Strategic Alliance to Contribute to the Treatment of Diabetes in Japan
Companies conclude joint sales agreement for two treatments
for type 2 diabetes mellitus - MP-513 and TA-7284 |
| January 31 |
|
Conference Call for FY2011 3rd Quarter Business Results [Material][Audio]
⇒[Q&A](February 6, 2012) |
| January 31 |
|
Announcement of FY2011 3rd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development" |
| January 16 |
|
Conclusion of Licensing Agreement for Hib Vaccine |
